A novel cell therapy made from tumor infiltrating lymphocytes (TILs) was superior to ipilimumab, and may be a new treatment option for advanced stage melanoma.
Melanoma incidence has been increasing in the United States over the last few decades. Some researchers argue that this is overdiagnosis, fueled by screening, especially among White patients.
/PRNewswire/ Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.
/PRNewswire/ Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.